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 The excellent study of the outcomes and costs





that chiropractors charged considerably more than primary
care physicians but had higher scores for patient satisfaction.
Neither finding is surprising. Although some chiropractors
advise patients to stop coming after their symptoms are gone,
others urge them to continue coming indefinitely for “preven-




Some chiropractic “practice-builders” encourage this and ac-
tually give seminars and write about virtually every type of





builders also teach how to increase patients’ satisfaction.
Whereas some of the techniques recommended are ethically
sound (and would be useful for physicians as well), others





Many chiropractors appear thorough because they ask
large numbers of irrelevant questions (such as whether pa-
tients had any falls during childhood) and perform large num-
bers of orthopedic and neurologic tests that are either redun-
dant or not pertinent. It would be interesting to know whether
patients’ degree of satisfaction was related to being told that
problems were due to “subluxations” (a chiropractic term for
misaligned vertebrae) that the chiropractor (with heroic ef-
fort) purported to correct.
I have observed the chiropractic marketplace closely for
over 25 years. Many chiropractors prescribe vitamin products
or homeopathic remedies to many of their patients. About 75









 It would be interesting to
know whether Carey et al. detected any such use in their
study. It would also be interesting to know whether there were
any differences in practice style between the chiropractors
who agreed to participate in the study and those who did not.
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 Physicians who treat acute low back pain al-
ready know that it is usually self-limited and almost always
resolves in a few days to a few weeks, leaving no residual ef-
fects, regardless of the treatment rendered. Radiography usu-
ally fails to reveal specific disease. Magnetic resonance imag-
ing is rarely indicated in the acute phase and often reveals
“abnormalities” that do not correlate with clinical symptoms
or findings.
The article by Carey et al. has already been interpreted by
the media as finding that the treatments provided by ortho-
pedic surgeons, chiropractors, and primary care physicians
are of equal value. In fact, however, the paper is flawed in
that the practitioners involved “were aware of the overall pur-
pose of the study.”
Furthermore, patients were included in the study after they
had selected practitioners, a method that obviously yielded re-
sults reflecting the patients’ biases and expectations about the
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optimal type of treatment. The authors provide no assurance
that the study patients were given the same treatment that
they might have been given in a nonstudy environment. . . .
Many patients treated for low back pain are victims of
work-related accidents or motor vehicle accidents. They are
different from those whose back pain develops at home or in
other situations in which a third party is not involved, and
they have different outcomes.
In the real world, assessment is further complicated by the
fact that plaintiffs’ attorneys often refer their clients to prac-
titioners who provide favorable diagnoses (with a poor prog-
nosis) and render prolonged and expensive treatment. In each















 None of the various types of providers studied
by Carey et al. produced appreciably better outcomes than
the others in patients with acute low back pain. The unavoid-
able conclusion is that the treatments offered by all were in-
effective. On the other hand, it is unacceptable to abandon
the 31 percent of patients who had not completely recovered
after six months, or the 5 percent who remained functionally
disabled after that time.
It should not be news nowadays that aggressive treatment
is not indicated during the first couple of weeks of low back
pain, that early mobilization is helpful, and that radiography
offers little benefit initially to patients with uncomplicated















 Any veteran family physician has learned by
experience that except for the temporary relief of pain, there
is no medication, physiotherapy, or “manipulation” that alters
the course of the usual musculoskeletal pain syndromes. Ex-
perienced physicians have also learned that if they share this

















 Dr. Goldstone is concerned that the patients
seeing each type of provider may have differed somewhat be-
cause they selected their own practitioners. We measured
multiple factors at base line, and the differences among the




To control for possible selection bias, we excluded patients
who were referred (an issue in the case of orthopedic sur-
geons) or had chronic back pain (an issue for doctors of chi-
ropractic). When we controlled for factors such as the pres-
ence of sciatica and base-line functional status, the differences
among groups of patients narrowed, indicating that further
control for the severity of low back pain would be unlikely to
reveal substantial differences among groups. Although it is
possible that practitioners altered their practice patterns be-
cause they knew they were in a study, we found little evidence,
for example, of reduced use of radiography by orthopedic sur-




 a controversial issue in those spe-
cialties. Our study is not unique. A study by Shekelle and col-
leagues, which we cited, found similar patterns of visits and
expenditures in the RAND Health Insurance Experiment, in
which the type of care given for back pain was not a primary
outcome and changes in physicians’ behavior would therefore




Dr. Shebar urges us not to “abandon” patients with chronic
back pain. We of course agree. Large studies have noted that
the majority of the social and health care costs for low back
pain are incurred by the small minority of patients (5 per-




 Improved methods of return-
ing these persons to full functioning are needed. The 31 per-
cent of patients who have minor residual symptoms do not,
in our view, require intensive rehabilitation. These patients
are back at work, can perform all the usual activities of daily
living, and have positive responses on just 1 or 2 of the 23





 These patients may be at increased risk of re-
currence, and we are still following our cohort to evaluate
this risk. They may also be candidates for improved strategies
of self-care. Our data do indicate that intensive evaluation
and treatment of all patients with acute back pain is unlikely
to be a cost-effective method of improving outcomes in such
patients.
The comments of Dr. Hampton and Dr. Barrett highlight
the differences between allopathic and chiropractic physicians
in their communication with patients. Over 75 percent of pa-
tients who see primary care physicians for back pain stay with
their index provider. We found some use of vitamins among
patients who see chiropractors, but we also found that these
patients use substantial amounts of nonsteroidal antiinflam-
matory drugs. Although allopathic physicians may criticize
the explanatory model used in chiropractic, their patients’ lev-
el of satisfaction may be lower than that of chiropractic pa-
tients because these physicians have no such model of their
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 With respect to the review of hereditary hem-




we would like to highlight some additional points in the rec-
ognition and management of this condition. A hallmark of he-
reditary hemorrhagic telangiectasia is profound variation in
severity between members of the same family. In one family





from mild disease that was barely apparent clinically to se-
vere visceral involvement. We have also seen families in which
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the disease is minor in multiple generations before being
manifested as pulmonary arteriovenous malformations in one
member in childhood. The phenotypic variation is not well
understood; the underlying mutation cannot be solely respon-
sible. One factor appears to be phenotypic modification by





 but may adversely affect disease progression,
particularly in the lungs. There is a female predominance of
pulmonary arteriovenous malformations, and deterioration in





pulmonary arteriovenous malformations are not restricted to






These findings have implications for clinical screening of
families with hereditary hemorrhagic telangiectasia, because
no affected member can be assumed a priori not to have a
pulmonary arteriovenous malformation. Clinical suspicion of
pulmonary arteriovenous malformations stems from a history
not just of stroke or cerebral abscess, but more often of mul-
tiple transient ischemic attacks, which may have been forgot-
ten or dismissed by the patient. All those at risk in a family
should be screened for pulmonary arteriovenous malforma-
tions once in childhood, once after puberty, before pregnancy,
and then at 10-year intervals. Screening can be done inexpen-
sively and safely with a method such as pulse oximetry (per-
formed for 10 minutes each with the subject in the standing
and supine positions) in conjunction with posteroanterior and




 Suspicious results should lead to
more extensive investigations with albumin microspheres la-





 A policy of five-year follow-up of
all persons with pulmonary arteriovenous malformations by





 would be very expensive and would ex-
pose young people to too much radiation. There are simpler,
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To the Editor: 
 
We are currently screening all members of
families with hereditary hemorrhagic telangiectasia in the
Danish county of Funen (500,000 inhabitants) for the pres-
ence of pulmonary arteriovenous malformations. The preva-





 All participants are clinically examined for
the presence of telangiectatic lesions, and pulse oximetry with
subjects in the supine and standing positions is performed. If
hereditary hemorrhagic telangiectasia is diagnosed or if the
oxygen saturation in either position is below 96 percent, con-
trast echocardiography is performed. Our preliminary data
suggest that pulmonary arteriovenous malformation can be
present in patients with normal oxygen saturation. Among 11
patients with untreated pulmonary arteriovenous malforma-





96 percent in the supine as well as the stand-
ing position.
Screening for the presence of pulmonary arteriovenous
malformation is recommended in late childhood and again at
the end of adolescence. The pulmonary arteriovenous malfor-
mations are usually diagnosed in young age groups and have
not been found as the first symptom of hereditary hemorrhag-
ic telangiectasia in older patients. In our study we have found
one 64-year-old man who was classified as not having hered-
itary hemorrhagic telangiectasia on clinical examination. Be-
cause there was a history of a transient ischemic attack and
low values were found on pulse oximetry (oxygen saturation,
94 percent in the supine position and 95 percent in the stand-
ing position), contrast echocardiography was performed and
showed a pulmonary arteriovenous malformation. The pa-
tient’s father had hereditary hemorrhagic telangiectasia in a
very mild form, without signs of pulmonary arteriovenous
malformation on contrast echocardiography, whereas two un-
cles and two aunts had pulmonary arteriovenous malforma-




 This particular case is of interest
because the patient had no history of either epistaxis or gas-
trointestinal bleeding. On clinical examination he only had a
few telangiectatic lesions on the trunk and none at the typical
sites, such as the nose, lips, mouth, conjunctivae, or fingers.
Our findings suggest that contrast echocardiography is a
safe and sensitive method for the diagnosis of pulmonary ar-
teriovenous malformations. The method should be used when
there are broad indications, especially in persons with a fam-
ily history of hereditary hemorrhagic telangiectasia with a
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To the Editor: 
 
Drs. Shovlin and Hughes highlight the pro-
found variations within families in manifestations of hereditary
hemorrhagic telangiectasia, as well as the serious complica-
tions sometimes seen with pregnancy. Determining whether
the causes of such variations and complications are hormonal,
genetic, or environmental (or some combination of the three)
will be critical to a full understanding of this condition.
Although pulmonary arteriovenous malformations can oc-
cur in anyone with hereditary hemorrhagic telangiectasia,
they are significantly more common in those in whom the dis-
ease is due to a mutation in the endoglin gene than in those





believe that variations among families are also crucial and
that clinicians need to be more aggressive in screening for
these malformations in families in which hereditary hemor-
rhagic telangiectasia is linked to the endoglin gene.
 
332 THE NEW ENGLAND JOURNAL OF MEDICINE Feb. 1, 1996
 
The question of how best to screen for pulmonary arteriove-
nous malformations is complex. Kjeldsen et al. point out that
pulse oximetry can be a helpful tool when the results are pos-
itive, but it misses a substantial number of these lesions. This
has been our experience as well. More sensitive screening




 shunt studies in-









these, both shunt studies and CT have the disadvantage of in-
volving exposure to radiation (at similar levels in each). How-
ever, CT is the most widely available method and the best at




Follow-up with helical CT is expensive and poses a risk
from radiation exposure. However, many patients with a his-
tory of a pulmonary arteriovenous malformation due to he-
reditary hemorrhagic telangiectasia have small, untreated




 Because these lesions may
grow sufficiently to lead to such complications as brain ab-
scess or stroke, in our view they warrant follow-up with tech-
niques that are more sensitive than positional oximetry and
that can detect the lesions before they become large enough
to cause neurologic sequelae.
The current debate about screening for pulmonary arterio-
venous malformations underscores the point that it is impos-
sible to define optimal practice for a number of aspects of
hereditary hemorrhagic telangiectasia without rigorous pro-
spective trials. Although such trials are often important in
common disorders, they are particularly necessary for condi-
tions that both are rare and exhibit genetic heterogeneity. Un-
til rigorous prospective studies are conducted of hereditary
hemorrhagic telangiectasia, reasonable and experienced peo-
ple will continue to disagree about a number of areas of diag-
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 on gene therapy for cystic fi-
brosis gave a very fair account of some of the difficulties in-
volved. We are concerned, however, that the two articles tak-
en together may send an unbalanced message. A study of




 with a trial
design very similar to that of Knowles et al., gave encourag-
ing results — a correction of the chloride-permeability defect
of approximately 20 percent without any adverse effects. Al-
though this is unlikely to be adequate for therapy, the under-
standing of liposome-mediated gene transfer is advancing
rapidly. We would therefore question whether the future lies
only in either immunosuppression to limit viral side effects
or the development of improved viral vectors as suggested,
rather than also in the development of more efficient nonviral
vectors.
We now know that both adenoviral-mediated and lipo-





) gene into human airway epi-
thelium in vivo is an inefficient process. Although these re-
ports are valuable and correct some of the overenthusiasm
surrounding gene therapy, it would be a great pity if they
pushed the pendulum too far the other way by ignoring the
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 Knowles et al. provided an excellent and long-
overdue randomized, double-blind appraisal of the prospects
for gene therapy that uses a first-generation adenoviral vector




 gene. Their observation
that local inflammatory responses probably blocked the cor-
rection of chloride transport by the adenoviral vector sur-
prised few researchers in the field. In fact, inflammation sec-
ondary to first-generation adenoviral vectors is thought to be








 article was sur-
prising. Many newspapers and news magazines published sto-
ries claiming, for example, that “scientists may have pushed









 The hyperbole can be traced back to the media, not to
participating scientists.
The vast majority of approved clinical trials of gene ther-
apy are focused on the safety, not the efficacy, of this new
technology. The continued focus on safety conflicts with the
rush to develop this technology and partially explains the
fact that gene therapy has yet to cure patients. Furthermore,
the complex and highly regulated approval process for gene-
therapy protocols, involving multiple reviews by local institu-
tions as well as reviews by the Food and Drug Administration
and the Recombinant DNA Advisory Committee of the Na-
tional Institutes of Health, prohibits an excessive or prema-
ture rush to the marketplace for gene therapy. Instead, cur-
rent gene-therapy research, such as the observations of
Knowles et al., sets the stage for future research — a process
integral to the scientific method. Many developments are al-
ready in progress for gene therapy of cystic fibrosis with the
use of new second-generation adenoviral vectors, adeno-asso-





ises of gene therapy will probably be fulfilled, but patients
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and the public must understand that the process is hard work
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 We remain enthusiastic about gene therapy,
despite the slower-than-hoped-for rate of progress and the in-









 One of the intents of our paper
was to alert researchers in the field to problems with the effi-
ciency of the adenovirus and consequently to stimulate new
approaches to increase the efficiency of this vector by the use
of other serotypes or new dosing strategies. Liposomes are
also less efficient than we would like, as evidenced by the fact




that Drs. Alton and Geddes mention were modest and tran-
sient (lasting a few days) and required repetitive dosing (every
10 to 15 minutes) for up to 7 hours. We agree with Drs. Alton
and Geddes that we should continue a broad-based approach
to the development of vectors, including liposomes, as empha-
sized in the last paragraph of our report. As Dr. Wagner in-
dicates, progress will result from iterative basic-science and
clinical-research studies. Our study revealed low-level gene
transfer and illustrates how quantitative this field has become.
Such is the expected course of events in a new area of applied





we remain optimistic that continued efforts will yield benefits
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 We wish to comment further on the possible
risks of hydroxyurea therapy in sickle cell disease, a subject
of considerable attention since the results of the Multicenter
Study of Hydroxyurea in Sickle Cell Anemia were reported by













 in their letters (Oct. 12 issue) is necessary. Unfortu-




 quoted by Ho
and Murgo distorts the thrust of our paragraph on the long-
term safety of hydroxyurea. Continued monitoring of patients
with sickle cell disease and others receiving hydroxyurea for
secondary cancers and other unanticipated side effects of this
drug is essential.
Equally important are the implications of data from the
multicenter study on hemoglobin F levels in patients treated
with hydroxyurea, presented on December 4, 1995, at the





 noted that between 25 percent and 50 per-
cent of the treated patients had no change in hemoglobin F
levels during two years of therapy, confirming earlier observa-





the multicenter study showing a strong correlation between
the clinical response and the hemoglobin F level were also
briefly reported.
These results, in our opinion, suggest that hemoglobin F
levels should be monitored closely in patients being treated
with hydroxyurea. If a marked increase in the level of hemo-
globin F (an absolute increase of at least several percentage
points) fails to occur after three to six months, consideration
should be given to discontinuing the drug. It is possible that
mechanisms other than the inhibition of hemoglobin-S po-
lymerization by hemoglobin F could make treatment with hy-
droxyurea beneficial. Until there is better evidence for these
postulated effects, however, they should not influence routine
decisions about therapy.
In addition, the fact that a considerable fraction of patients
do not have a response to hydroxyurea reinforces our plea for





 to effect greater responses in hemo-
globin F levels and possibly greater clinical benefits. A recent
report to the director of the National Institutes of Health is





 It is also essential that the results of
current therapies, based on modulating endogenous gene ex-
pression, not be overinterpreted, which might result in a de-
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 Charache et al. report a 44 percent reduction
in the median annual rate of painful crises in adults with sick-
le cell disease treated with oral hydroxyurea. However, the
long-term risks of such treatment remain unclear. Although
melanonychia (hyperpigmentation of the nails) has been re-





 this finding has not been reported in pa-
tients with sickle cell disease. Hydroxyurea-induced horizontal
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there are only a few cases with the hydroxyurea-induced lon-




We treated six adults with sickle cell disease (four women
and two men; age range, 18 to 45 years) with hydroxyurea (1
to 1.5 g daily). Five of the six patients had hemoglobin SS dis-







therapy, each patient had reported at least three severe pain-
ful events per year requiring parenteral analgesics.
After six months of treatment with hydroxyurea, five of the
six patients reported a decrease in the number of painful
events. Melanonychia developed in two of the four women af-
ter six weeks of therapy. The 20 nailbeds of each affected
woman showed heterogeneous patterns of nonpainful longitu-
dinal bands to the tips of the nails, as well as diffuse horizon-
tal bands of hyperpigmentation (Fig. 1). The longitudinal
bands ranged from 0.5 to 4 mm in width, whereas the hori-
zontal bands appeared diffuse and were difficult to measure.
The nails did not appear to be thickened or atrophic, and the
adjacent skin was normal.
One of the two affected women had a small area of hyper-
pigmentation on the left lateral aspect of the tongue, as well
as on her palms and soles, suggesting a systemic effect. The
face, gums, and buccal mucosa have not been involved to
date. In the other woman, only the nails were involved. The
two affected patients considered discontinuing hydroxyurea
because of this undesirable cosmetic effect. However, both pa-
tients decided to continue taking the drug because of the re-
duction in painful events.
We do not know of predisposing factors for melanonychia
and whether this cosmetic feature will have a negative effect
on compliance with treatment. It may be reversible, as has
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 In the report of Kline et al. describing an out-





the 14 active tuberculosis cases occurred among patients se-
ronegative for the human immunodeficiency virus who had
positive tuberculin tests but normal chest radiographs. This




; among contacts of patients with
active tuberculosis on Navy ships, 3 to 25 percent of those
whose tuberculin skin tests converted from negative to posi-
tive had positive sputum cultures despite having normal chest




 Kent et al. obtained daily cultures
for one month from 12 patients with recently converted tuber-









 Given the more sensitive techniques
now available for detecting 
 
M. tuberculosis, the actual propor-
tion may be even higher.5 The optimal treatment for culture-
positive patients with normal chest radiographs and their de-
gree of infectiousness are not known.
All four patients in the study by Kline et al. who had posi-
tive cultures with normal chest radiographs had cough, and
two had weight loss. This suggests that tuberculin conversion
may not always be asymptomatic, that these symptoms may
be common among people with a history of alcohol and ciga-
rette use, or that active tuberculosis disease was in the proc-
ess of developing in these patients. Perhaps tuberculosis infec-
tion, like primary HIV infection, may be characterized by a
distinct symptom complex.6
The authors conducted a prompt and thorough investiga-
tion in a difficult context, effectively limiting the further
spread of tuberculosis. The thoroughness of their evaluations
may have identified several patients with positive cultures in
whom active tuberculosis would not have developed.
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HEALING BY DESIGN
To the Editor: In Horsburgh’s “Healing by Design” (Sept.
14 issue),1 he does not mention the pernicious way in which
medical economic pressures are influencing modern hospital
design. Hospitals in competition with one another for paying
Figure 1. Fingernails of a 31-Year-Old Black Woman with Hemo-
globinopathy SS and Hydroxyurea-Induced Melanonychia Char-
acterized by Longitudinal (Large Arrow) and Diffuse Horizontal
(Small Arrow) Bands.
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patients spend extravagantly for lobbies and entrances more
appropriate for a bank or Las Vegas hotel, while cutting
back on professional and ancillary staffing to try to improve
their bottom lines. Compounding the problem is the desire
of philanthropists to erect impressive testimonials to their
generosity.
Simple but relatively skilled and labor-intensive care re-
mains the key to managing many common and compelling
medical problems.2 Building fantasy-vacation hospitals in an
age when American hospitals are ruthlessly cutting profes-
sional and ancillary staff strikes me as inappropriate hus-
bandry of our health care resources.
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To the Editor: As Dr. Horsburgh points out, the recent inter-
est in hospital design has focused appropriately on patients
and their families as the “consumers” of hospital services. To
achieve the goal of optimizing health care delivery, however,
hospital design must also optimize coordination among health
care providers. For example, horizontal spaces in hospitals
encourage face-to-face interaction between health care pro-
viders, sometimes facilitating consultation or important dis-
cussions regarding the treatment of patients.1 Health care
providers at the old Peter Bent Brigham Hospital in Boston
(where “pavilion style” ward buildings were connected by a
single conduit affectionately called “The Pike”) or at the Cleve-
land Clinic Foundation (where the “Skyway,” a horizontal, el-
evated walkway, connects the hospital to the outpatient build-
ing) appreciate the advantages of horizontal spaces that
encourage face-to-face meetings and interactions. Also, hav-
ing alcoves along hospital corridors permits private conversa-
tions, thereby averting the hazards of “elevator talk.”2
JAMES K. STOLLER, M.D.
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Dr. Horsburgh replies:
To the Editor: I share Dr. Forman’s dismay that some hospi-
tals have spent large sums for sumptuous spaces that have lit-
tle effect on patient care. Good design can provide positive
symbolic meaning without opulence. Such misguided expend-
itures emphasize the importance of involving health care pro-
viders in the design process.
Dr. Stoller identifies additional positive attributes of hori-
zontal hospitals that have contributed to the increase in con-
struction of such facilities in the past decade.
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